 |
Prospector
Profile
111-05
|
| |
| ActivBiotics, Inc. |
NAICS |
541710 |
| 110 Hartwell Ave
Lexington, MA 02421 |
Description |
Biotechnology |
| (781) 372-4800 |
Employees |
21 |
| http://www.activbiotics.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-23.4480 |
| |
Assets |
(mil) |
27.7230 |
| |
Liability |
(mil) |
95.4210 |
| |
(for the year ended 2005-12-31) |
| |
|
Category:
IP Asset Sale
|
| |
|
Event:
ActivBiotics, Inc., said that upon reviewing strategic options after its clinical trial of Rifalazil failed in peripheral arterial disease patients, it will sell all or substantially all of its assets on an "as is" basis through an Assignment for the Benefit of Creditors process. The Assignee of the assets is Mr. Joseph Finn, Jr., CPA, of Finn, Warnke & Gayton. The bidding for the assets, which may be purchased separately or in combination, started on Dec. 18, 2007 and will end on Feb. 1, 2008.
|
| |
|
Intellectual Property:
The Company currently owns or exclusively licenses a total of 6 U.S. patents and 13 U.S. patent applications that are material to its current development of Rifalazil and M40403, as well as numerous foreign counterparts to many of these patents and patent applications. The material U.S. patent rights relating to Rifalazil as an anti-Chlamydial agent expire beginning in 2013 while the material U.S. patent rights relating to M40403 expire beginning in 2014. The Company is a party to a license agreement with Kaneka Corporation relating to patents, patent applications and know-how directed to a particular class of antibiotics, which includes Rifalazil. Additionally, the Company holds a license from Pfizer to patents, patent applications and know-how directed to SOD mimetic technology generally and M40403 specifically. It also has a license agreement with the University of Washington for patents, patent applications and other technology rights for use in the diagnosis and treatment of arterial Chlamydial granuloma, a form of inflammation found in tissues, including related arterial and coronary diseases and disorders caused by or influenced by arterial Chlamydial granuloma lesions and infections. [SEC Filing S-1 08-14-06]
|
| |
|
Description:
ActivBiotics is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of inflammatory diseases and bacterial infections.
|
| |
|
Officers:
Steven C. Gilman (Chair & CEO); Glenn Kazo (Chief Business Officer); Suzzane Cadden (VP); Melissa Packard (VP); Andrew Sternlicht (VP); John van Duzer (VP)
|
| |
|
Auditor:
KPMG LLP
|
| |
| |
| |
| return to main page |
|
|
